Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases
Authors:
- Inge M AppelIAInge M Appel
- Wim Cj HopWHWim Cj Hop
- Rob PietersRPRob Pieters
- 1 March 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 17 (2) , 139-146
Abstract
Alterations in hemostasis have frequently been observed in children with acute lymphoblastic leukemia. Thrombotic events are well documented in patients receiving L-asparaginase as a single agent or in combination with other chemotherapeutic drugs. The present prospective, randomized study evaluated the effect of two different L-asparaginase preparations, native Escherichia coli L-asparaginase (Crasnitin; Bayer AG, Leverkusen, Germany; n = 10) and L-asparaginase derived from Erwinia chrysanthemi (Erwinase; Porton Pruducts, London, UK; n = 10) on the changes in parameters concerning hypercoagulability. Patients were randomized to receive a total of eight doses of 10,000 IU/m2 L-asparaginase intravenously with intervals of 3 days during induction therapy. Before starting L-asparaginase treatment all patients had already demonstrated an increased thrombin generation shown by the elevated levels of prothrombin fragment 1+2 and thrombin antithrombin III, presumably due to therapy with prednisone, daunorubicin and vincristine. A significant decrease in alpha2-antiplasmin and plasminogen levels was measured in the E. coli L-asparaginase but not in Erwinase-treated patients. Increased thrombin generation combined with a decrease in alpha2-antiplasmin and plasminogen levels may lead to a state of increased risk for thrombosis due to a delay in fibrin elimination in E. coli L-asparaginase-treated patients only.Keywords
This publication has 28 references indexed in Scilit:
- Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation systemBritish Journal of Haematology, 2001
- Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemiaKlinische Padiatrie, 1999
- Coagulation and fibrinolysis in children with acute lymphoblastic leukaemia treated according to the COALL-05-92-protocolKlinische Padiatrie, 1998
- Changes in coagulation and fibrinolysis in childhood ALL: a two‐step dose reduction of one E. coli asparaginase preparationBritish Journal of Haematology, 1996
- Inhibition of hypercoagulation by antithrombin substitution in E. coli L‐asparaginase‐treated childrenEuropean Journal of Haematology, 1996
- Minimal effects ofE. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: A randomized studyMedical and Pediatric Oncology, 1994
- Influence of blood sampling from venipunctures and catheter systems on serial determinations of prothrombin activation fragment 1 + 2 and thrombin-antithrombin III complexAnnals of Hematology, 1993
- Circadian Variation of Fibrinolytic Activity in BloodChronobiology International, 1991
- Non‐randomised study comparing toxicity of escherichia coli and erwinia asparaginase in children with leukaemiaMedical and Pediatric Oncology, 1990
- Gerinnungsphysiologische Schnellmethode zur Bestimmung des FibrinogensActa Haematologica, 1957